The Field PULSE Study

A Pre-Market, First-In-Human, Pilot, Interventional, Clinical Investigation to Evaluate Safety and Feasibility of the FieldForce™ Ablation System in Patients With Atrial Fibrillation

This is a pre-market, first-in-human, pilot, interventional, clinical investigation that aims to evaluate safety and feasibility of the FieldForce™ Ablation system in patients with atrial fibrillation who are indicated for an AF catheter ablation.

Study Overview

• Status: Active, not recruiting
• Conditions: Atrial Arrhythmias
• Intervention / Treatment: Device: FieldForce Ablation System

Detailed Description

Atrial fibrillation (AF) is a cardiac rhythm disorder characterized by irregular and often abnormally fast contractions of the atrial cardiomyocytes resulting in various symptoms, including palpitations, dizziness, shortness of breath and tiredness.

AF is the most common sustained cardiac arrhythmia, having a prevalence of about ≈2% in the general population. AF can be associated with increased morbidity and mortality in patients with cardiovascular disease, and increased risk of stroke in general population.

Catheter ablation for the treatment of AF is primarily performed with radiofrequency (RF) or cryoballoon (CB) catheters to achieve anatomic pulmonary vein isolation (PVI). However, the technical challenges of achieving effective PVI and recognized risks of complications are two most important factors driving the need for replacing thermal ablation technologies like RF and CB.

Pulsed field ablation (PFA) is a non-thermal ablation technology which uses high voltage pulsed electrical fields to ablate tissues. This destabilizes cell membranes by forming irreversible nanoscale pores and leakage of cell contents, culminating in cell death. Several clinical studies have demonstrated that PFA can achieve pulmonary vein isolation with minimal collateral damage in a time-efficient manner.

The FieldForce™ Ablation System utilizes PFA with an innovative electrode technology called FieldBending™ designed to improve safety, tolerability, and efficacy for focal deflectable catheters used for the treatment of AF.

• Study Type: Interventional
• Enrollment (Actual): 35
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Czechia
  • Prague, Czechia, 150 00
    • Na Homolce Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Signed patient informed consent form (ICF).
2. Female and male patients aged ≥ 18 and ≤ 80.
3. Documented atrial fibrillation via an electrocardiogram (must be at least 30 seconds) within one year of enrollment.
4. Indicated for a first-time catheter ablation for atrial fibrillation or associated atrial arrhythmias (European guidelines).

Exclusion Criteria:

1. Body Mass Index > 40.
2. Ineligible for ablation (including but not limited to known left atrial thrombus).
3. AF secondary to electrolyte imbalance, thyroid disease, alcohol abuse or other reversible/non-cardiac causes.
4. Previous endocardial/epicardial ablation or surgery for AF.
5. NYHA Class IV.
6. Left atrial appendage device or occlusion within 180 days.
7. Atrial or ventricular septal defect closure.
8. Atrial myxoma.
9. The presence of inferior vena cava embolic protection filter devices.
10. Significant or symptomatic untreated hypotension, bradycardia, or chronotropic incompetence.
11. History of hemodynamically severe valvular disease. Severity should be assessed using echocardiography, according to AHA and European guidelines.
12. Diagnosis of pacemaker dependance.
13. Uncontrolled abnormal bleeding and/or clotting disorder.
14. Contraindication to systemic or oral anticoagulation.
15. Serious or untreated medical conditions that would prevent participation in the study, interfere with assessment of therapy, or confound data or its interpretation, including but not limited to solid organ or hematologic transplant, or currently being evaluated for an organ transplant.
16. History of severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea which may interfere with the assessment of the therapy.
17. Active malignancy.
18. Uncontrolled clinically significant infection.
19. Life expectancy is less than one year.
20. Clinically significant psychological condition that in the investigator's opinion would prohibit the subject's ability to meet the study requirements.
21. Any of the following within 3 months of enrollment: myocardial infarction, unstable angina, percutaneous coronary intervention, heart surgery (coronary artery bypass grafting/atriotomy), stroke or transient ischemic attack (TIA);
22. Participation in another investigational study that would interfere with this study.
23. Patient is not able to understand the nature of this study or is unwilling or unable to attend the study procedures.
24. Women who are of childbearing age and not on a reliable form of birth control.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Catheter ablation; Adult patients with a history of atrial fibrillation or associated atrial arrhythmias and indicated for a catheter ablation.

Device: FieldForce Ablation System; The FieldForce Ablation System is indicated for cardiac electrophysiologic mapping, delivery of diagnostic pacing stimuli, and pulse field ablation of cardiac tissue. When used with the FieldForce Ablation Catheter, the FieldForce System is intended to be used in the right/left atria and/or left/right ventricle to deliver PFA ablation lesions in the selected areas of the chamber.; Other Names: Pulse Field Ablation

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Performance	To characterize the proportion of subjects who achieved pulmonary vein isolation (PVI) using the FieldForce™ Ablation System	index procedure and 3 months
Incidence of early and late onset adverse events	Adverse events to evaluate the safety of the FieldForce™ Ablation System will be collected. The incidence of the major safety events will be evaluated.	30 days and 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Device or Procedure Related SAEs	Proportion of subjects reporting one or more device-or procedure-related SAEs.	30 days, 3 months, 6 months and 12 months
Procedure Time	To characterize procedure times (including total duration, transpired ablation time, fluoroscopy time).	Index procedure
Presence of Atrial Arrhythmias from index procedure through end of study	To evaluate freedom from atrial arrhythmia (including atrial fibrillation, flutter, or tachycardia).	6 months and 12 months

Collaborators and Investigators

• Sponsor: Field Medical

Study record dates

Study Major Dates

• Study Start (Actual): July 25, 2024
• Primary Completion (Estimated): June 30, 2027
• Study Completion (Estimated): December 31, 2027

Study Registration Dates

• First Submitted: June 5, 2024
• First Submitted That Met QC Criteria: June 5, 2024
• First Posted (Actual): June 11, 2024

Study Record Updates

• Last Update Posted (Actual): May 14, 2026
• Last Update Submitted That Met QC Criteria: May 13, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: atrial fibrillation; PFA; atrial arrhythmia; Pulse Field Ablation
• Additional Relevant MeSH Terms: Cardiovascular Diseases; Pathologic Processes; Heart Diseases; Arrhythmias, Cardiac; Pathological Conditions, Signs and Symptoms; Atrial Fibrillation; Investigative Techniques; Therapeutics; Clinical Laboratory Techniques; Cytological Techniques; Electrochemical Techniques; Electroporation Therapies; Electroporation; Irreversible Electroporation Therapy
• Other Study ID Numbers: CLN-PULSE-PR-01

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: Yes